Thrombotic Complications in Immune Thrombocytopenia Patients Treated with Avatrombopag

Author:

Abdelsamia Mahmoud1,Farid Saira2,Dean Steven2,Cataland Spero R.2ORCID

Affiliation:

1. Department of Medicine, Michigan State University, East Lansing, MI 48824, USA

2. Department of Medicine, Ohio State University, Columbus, OH 43210, USA

Abstract

Avatrombopag is a novel oral non-peptide thrombopoietin receptor agonist (TPO-RA) that was approved by the FDA as a second-line therapy for chronic immune thrombocytopenia (cITP). Avatrombopag has shown promising results in regards to efficacy and tolerability, but to our knowledge, there are no reports of thrombotic complications associated with avatrombopag. We present two patients with chronic ITP who suffered thromboembolic events shortly after starting treatment with avatrombopag. The first case is that of a 30-year-old female with refractory cITP who failed multiple lines of ITP therapy and was hospitalized with an intracranial bleed. The patient eventually recovered after an emergent splenectomy but subsequently developed a right lower lobe pulmonary embolism three weeks after starting treatment with avatrombopag. The second case is that of a 58-year-old female with a prolonged history of ITP, and no prior history of peripheral vascular disease, who suffered from both arterial and venous thrombotic events four weeks after starting avatrombopag. Given the new arterial and venous thrombotic complications, avatrombopag was stopped. She was challenged with avatrombopag again and developed yet another thrombotic complication.

Publisher

MDPI AG

Subject

Hematology

Reference17 articles.

1. Dova Pharmaceuticals (2019, July 03). Dova Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for Doptelet (Avatrombopag) for Treatment of Chronic Immune Thrombocytopenia (ITP). 27 June 2019. Available online: https://dova.com/wp-content/uploads/2019/06/doptelet-itp-approval-press-release-6-26-19.pdf.

2. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia;Jurczak;Br. J. Hematol.,2018

3. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia;Bussel;Blood,2014

4. Risk of arterial thrombotic and venous thromboembolic events in patients with primary chronic immune thrombocytopenia: A Scandinavian population-based cohort study;Cetin;Br. J. Haematol.,2016

5. Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database;Sarpatwari;Haematologica,2010

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Multiple drugs;Reactions Weekly;2023-11-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3